VIENNA—For women with premenopausal breast cancer the benefits of using the most adjuvant endocrine treatment needs to be weighed against additional side effects—according to Marco Colleoni MD from the European Institute of Oncology in Milan. After his talk at the St Gallen breast cancer conference he discussed criteria for individualizing optimal endocrine adjuvant treatments with Oncology Times reporter Sarah Maxwell.
You may also like...
Audio Journal of Oncology in Advance – March 1st, 2008 4 Mar, 2008 Chimeric antigen receptor T-cell therapy rescues kids with relapsing acute lymphoblastic leukaemia 6 Aug, 2013 Young Women with HER2+ Early Breast Cancer Better with Mastectomy 24 Aug, 2016 Androgen blockade: 18 as good as 36 months in radiotherapy-treated prostate cancer 24 Mar, 2013
- Previous story Genetic Tests for Breast Cancer Late Recurrence Risk—Not Yet Ready for Prime Time
- Next story Deep Genomic Profiling in Breast Cancer Promises to Improve Outcomes
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014